In vitro inhibitory effects of troglitazone and its metabolites on drug oxidation activities of human cytochrome P450 enzymes: comparison with pioglitazone and rosiglitazone

References

• Fu, Y., Si, C., FunTA, T. and FOOTE, C. S., 1996, Photooxidation of troglitazone, a new antidiabetic drug. Photochemistry and Photobiology, 63, 615–620.
   PubMedGoogle Scholar
• GUENGERICH, F. P., 1994, Analysis and characterization of enzymes. In A. W. Hayes (ed.), Principles and Methods of Toxicology (New York: Raven), pp. 1259–1313.
   Google Scholar
• GUENGERICH, F. P., 1995, Human cytochrome P450 enzymes. In P. R. Oritiz de Montellano (ed.), Cytochronw P450 (New York: Plenum), pp. 473–535.
   Google Scholar
• GUENGERICH, F. P. and SHIMADA, T., 1991, Oxidation of toxic and carcinogenic chemicals by human cytochrome P-450 enzymes. Chemical Research in Toxicology, 4, 391–407.
   PubMed Web of Science ®Google Scholar
• Izuw, T., ENOMOTO, S., HOSHIYAMA, K., SASAHARA, K. and SUGIYAMA, Y., 1997a, Pharmacokinetic stereoselectivity of troglitazone, an antidiabetic agent, in the KK mouse. Biopharmaceutical and Drug Disposition, 18, 305–324.
   PubMedGoogle Scholar
• Izuw, T., HOSHIYAMA, K., ENOMOTO, S., SASAHARA, K. and SUGIYAMA, Y., 1997b, Pharmacokinetics of troglitazone, an antidiabetic agent: prediction of in vivo stereoselective sulphation and glucuron-idation from in vitro data. Journal of Pharmacology and Experimental Therapeutics, 280,1392–1400.
   PubMedGoogle Scholar
• KAPLAN, B., FRIEDMAN, G., JAcoss, M., Viscuso, R., LYMAN, N., DEFRANCO, P., BONOMINI, L. and MULGAONICAR, S. P., 1998, Potential interaction of troglitazone and cyclosporine. Transplantation, 65, 1399–1400.
   PubMed Web of Science ®Google Scholar
• KAWAI, K., KAWASAKI-TOKUI, Y., ODAKA, T., TSURUTA, F., KAZUI, M., IWABUCHI, H., NAKAMURA, T., KrNomirrA, T., IKEDA, T., YOSHIOKA, T., KOMAI, T. and NAKAMURA, K., 1997, Disposition and metabolism of the new oral antidiabetic drug troglitazone in rats, mice and dogs. Arzneimittel Forschung, 47, 356–368.
   Google Scholar
• KAWAI, K., ODAICA, T., TsuKurA, F., ToKul, T., IKEDA, T. and NAKAMURA, K., 1998, Stereoselective metabolism of new oral anti-diabetic agent troglitazone stereoisomers in liver. Xenobiotk Metabolism and Disposition, 13, 362–368.
   Google Scholar
• KOUP, J. R., ANDERSON, G. D. and Loi, C. M., 1998, Effect of troglitazone on urinary excretion of 6fi-hydroxycortisol. Journal of Clinical Pharmacology, 38, 815–818.
   PubMed Web of Science ®Google Scholar
• KURAMOTO, K., Sthiwzu, N. and TODA, G., 1998, Liver dysfunction associated with troglitazone (Noscal0). Rinsho-Iyaku, 14, 461–466.
   Google Scholar
• LOWRY, 0. H., ROSEBROUGH, N. J., FAR, A. L. and RANDALL, R. J., 1951, Protein measurement with the Folin phenol reagent. Journal of Biological Chemistry, 193, 265–275.
   Google Scholar
• NAKAJIMA, M., OHYAMA, K., NAICAMURA, S., SHIMADA, N., YAMAZAKI, H. and YoKoi, T., 1999, Inhibitory effects of azelastine and its metabolites on drug oxidation catalyzed by human cytochrome P-450 enzymes. Drug Metabolism and Disposition, 27, 792–797.
   PubMed Web of Science ®Google Scholar
• NELSON, D. R., KOYMANS, L., KAMATAKI, T., STEGEMAN J. J., FEYEREISEN, R., WAXMAN, D. J., WATERMAN, M. R., GOTOH O., COON, M. J., ESTABROOK, R. W., GUNSALUS I. C. and NEBERT, D. W., 1996, P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics, 6, 1–42.
   Google Scholar
• ODAKA, T., KAWAI, K., TSURUTA, F., IKEDA, T., KINOSHITA, T., NAKAMURA, K., SHIMADA, M. and YAMAZOE, Y., 1995, Pharmacokinetics of troglitazone (CS-045), a new oral antidiabetic drug: phase I and phase II metabolism in female rats. Xenobiotic Metabolism and Disposition, 10 (suppl.), S–386.
   Google Scholar
• OMURA, T. and SATO, R., 1964, The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. Journal of Biological Chemistry, 239, 2370–2378.
   PubMed Web of Science ®Google Scholar
• PDR, 1999, REZULIN €?'. In Physicians' Desk Reference (Montvale: Medical Economics Co.), pp. 2310–2314.
   Google Scholar
• SPARANO, N. and SEATON, T. L., 1998, Troglitazone in type II diabetes mellitus. Pharmacotherapy,, 18, 539–548.
   PubMedGoogle Scholar
• WATKINS, P. B. and WiirrcomB, R. W., 1998, Hepatic dysfunction associated with troglitazone. New England Journal of Medicine, 338, 916–917.
   PubMed Web of Science ®Google Scholar
• YAMAZAKI, H., INDuE, K., CHB3A, K., OZAWA, N., KAWAI, T., SUZUKI, Y., GOLDSTEIN, J. A., GUENGERICH, F. P. and SHIMADA, T., 1998a, Comparative studies on the catalytic roles of cytochrome P450 2C9 and its Cys- and Leu- variants in the oxidation of warfarin, flurbiprofen, and diclofenac by human liver microsomes. Biochemical Pharmacology, 56, 243–251.
   Google Scholar
• YAMAZAKI, H., INDuE, K. and SIRMADA, T., 1998b, Roles of two allelic variants (Arg144Cys and Ile359Leu) of cytochrome P450 2C9 in the oxidation of tolbutamide and warfarin by human liver microsome. Xenobiotica, 28, 103–115.
   PubMed Web of Science ®Google Scholar
• YAMAZAKI, H., NAKAJIMA, M., SHB3ATA, A., SUZUKI, M., SHIMADA, N., GUENGERICH, F. P. and YOKOI T., 1999a, Oxidation of troglitazone to a quinone-type metabolite catalyzed by cytochrome P450 2C8 and P450 3A4 in human liver microsomes. Drug Metabolism and Disposition 27.
   Google Scholar
• YAMAZAKI, H. and SHIMADA, T., 1999, Effects of arachidonic acid, prostaglandins, retinol, retinoic acid, and cholecalciferol on xenobiotic oxidations catalysed by human cytochrome P450 enzymes. Xenobiotica, 29, 231–241.
   PubMed Web of Science ®Google Scholar
• YAMAZAKI, H., TANAKA, M. and SHIMADA, T., 1999b, Highly sensitive HPLC assay for coumarin 7-hydroxylation and 7-ethoxycoumarin 0-deethylation by human liver cytochrome P450 enzymes. Journal of Chromatography B: Biomedical Applications, 721, 13–19.
   Google Scholar